Cointime update: BeiGene announced that its wholly owned subsidiary BeiGene Switzerland will invest $19.5 million in cash in Bravera Bio’s Series A round alongside affiliate Baker Bros entities and other investors, and will convert $500,000 of SAFE interests into Series A preferred shares. Upon completion, BeiGene Switzerland will hold 9.477% of Bravera. The transaction is a related-party deal but not a major asset restructuring, and requires no board or shareholder approval.
BeiGene to Invest $19.5M in Bravera Series A
Share on WeChat
Open WeChat → Scan → then tap "…" to send to a chat or Moments.
Tap "…" in the top-right corner to send to a chat or share to Moments.
Related News
40m ago
Nvidia beats estimates; analysts flag lingering uncertainty over outlook
1h ago
Binance to Launch USDT Perpetual Contracts for Six TradFi Assets
5h ago
Anthropic Expected to Price IPO Above Range at $80+ Per Share
5h ago
Ark Invest Buys $2.7M of Block Shares as Stock Falls 4.4%
6h ago
Nvidia beats estimates; NVDA perp on Hyperliquid rises 4% to $161.7
7h ago
Anthropic Existing Investors Plan Billions in IPO Share Purchase